2 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow NMIBC: new trials by email Literature Review of NMIBC trials Research Report on NMIBC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG Intravesical Recombinant Mycobacterium (rMBCG) - NMIBC | Phase 1 / Phase 2 | Recruiting | ImmunityBio, Inc. | 40 | 2025-10-15 | 2026-03-27 |
| RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects RC48-ADC in Combination with gemcitabine - NMIBC | Phase 2 | Recruiting | RemeGen Co., Ltd. | 85 | 2023-06-08 | 2023-07-13 |
Non-Muscle Invasive Bladder Neoplasms (2)
Carcinoma (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Urinary Bladder Diseases (2) · Urinary Bladder Neoplasms (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2) · Urologic Neoplasms (2)
Gemcitabine (1)
ImmunityBio, Inc. (1) · RemeGen Co., Ltd. (1)
China (1) · United States (1)